PMID- 9741068
OWN - NLM
STAT- MEDLINE
DCOM- 19981207
LR  - 20131121
IS  - 1057-9249 (Print)
IS  - 1057-9249 (Linking)
VI  - 7
IP  - 4
DP  - 1998 Jul-Aug
TI  - A controlled trial of fluoxetine and desipramine in depressed women with advanced 
      cancer.
PG  - 291-300
AB  - BACKGROUND: This study was conducted to determine the efficacy and tolerability 
      of fluoxetine and desipramine in treating depressive symptoms in women with 
      cancer. METHOD: In this prospective, 6-week, double-blind, placebo-controlled 
      trial, we compared fluoxetine with desipramine in treating depressive symptoms in 
      40 women diagnosed with cancer. Scales used to measure efficacy and tolerability 
      were the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating 
      Scale (HAM-A), the Clinical and Patient's Global Impression (CGI and PGI) scales, 
      the Functional Living Index for Cancer (FLIC), the Memorial Pain Assessment Card 
      (MPAC), and the SF-36 Health Survey. RESULTS: Fluoxetine and desipramine 
      treatments improved depression and anxiety symptoms. There was a trend towards 
      significance in improvement of FLIC scores (as evidenced by greater numerical 
      improvements with fluoxetine treatment). Fluoxetine treatment alone was 
      associated with statistically significant improvements in MPAC Mood scale scores. 
      Both treatments showed statistically significant improvements in the quality of 
      life SF-36 scores in Role Emotional, Social Functioning, Mental Health, and 
      Vitality. CONCLUSIONS: Both fluoxetine and desipramine were effective and 
      well-tolerated in improving depressive symptoms and quality of life in women with 
      advanced cancer. Fluoxetine may offer greater benefit to these patients, as 
      evidenced by greater improvements in fluoxetine-treated patients on several 
      quality of life measures. Our results, while meaningful, should be confirmed in a 
      larger patients sample. However, experience from studies of antidepressant use in 
      patients with advanced cancer has shown that intercurrent disease and treatment 
      variables make it difficult to conduct large studies.
FAU - Holland, J C
AU  - Holland JC
AD  - Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer 
      Center, New York, NY, USA.
FAU - Romano, S J
AU  - Romano SJ
FAU - Heiligenstein, J H
AU  - Heiligenstein JH
FAU - Tepner, R G
AU  - Tepner RG
FAU - Wilson, M G
AU  - Wilson MG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Psychooncology
JT  - Psycho-oncology
JID - 9214524
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 01K63SUP8D (Fluoxetine)
RN  - TG537D343B (Desipramine)
SB  - IM
MH  - Antidepressive Agents, Second-Generation/*administration & dosage
MH  - Antidepressive Agents, Tricyclic/*administration & dosage
MH  - Depressive Disorder/*drug therapy/etiology
MH  - Desipramine/*administration & dosage
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluoxetine/*administration & dosage
MH  - Humans
MH  - Middle Aged
MH  - Neoplasms/complications/*psychology
MH  - Prospective Studies
MH  - Quality of Life
MH  - Treatment Outcome
EDAT- 1998/09/19 00:00
MHDA- 1998/09/19 00:01
CRDT- 1998/09/19 00:00
PHST- 1998/09/19 00:00 [pubmed]
PHST- 1998/09/19 00:01 [medline]
PHST- 1998/09/19 00:00 [entrez]
AID - 10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.0.CO;2-U [doi]
PST - ppublish
SO  - Psychooncology. 1998 Jul-Aug;7(4):291-300. doi: 
      10.1002/(SICI)1099-1611(199807/08)7:4<291::AID-PON361>3.0.CO;2-U.